Patents Represented by Attorney, Agent or Law Firm Mark R. Daniel
  • Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
    Patent number: 5270324
    Abstract: Compounds having the formula I: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
    Type: Grant
    Filed: April 10, 1992
    Date of Patent: December 14, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert Zamboni, Daniel Guay, Marc LaBelle
  • Hydroxyalkylquinoline ether acids as leukotriene antagonists
    Patent number: 5266568
    Abstract: Compounds having the formula I: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
    Type: Grant
    Filed: October 10, 1991
    Date of Patent: November 30, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Michel L. Belley, Yves LeBlanc, Marc Labelle
  • Chiral catalysts for reduction of ketones and process for their preparation
    Patent number: 5264585
    Abstract: The chiral catalyst of general structure 1, or its enantiomer ##STR1## is prepared by treating the corresponding N-carboxy anhydride of structure 2 ##STR2## with an aryl metal, especially a phenyl metal such as an aryl magnesium halide, aryl lithium, aryl zinc or aryl cesium, to form a 1,1-diaryl- methanol of structure 3 ##STR3## followed by treatment with a compound of structure, 4 ##STR4## The catalyst, wherein R is aromatic, is novel and in some cases superior to the catalyst wherein R is alkyl or aralkyl in directing the chirality of diborane, borane-dimethyl sulfide or borane-tetrahydrofuran reductions of ketones to secondary alcohols.
    Type: Grant
    Filed: October 26, 1992
    Date of Patent: November 23, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Thomas J. Blacklock, Todd K. Jones, David J. Mathre, Lyndon C. Xavier
  • Preparation of oxazaborolidine borane complex
    Patent number: 5264574
    Abstract: Oxazaborolidine-borane complexes are prepared by adding a C.sub.5-8 alkane, typically hexane, to an aged solution of oxazaborolidine and a source of borane such as borane-dimethyl sulfide or gaseous diborane to crystallize the oxazaborolidine complex.
    Type: Grant
    Filed: April 3, 1992
    Date of Patent: November 23, 1993
    Assignee: Merck & Co., Inc.
    Inventors: James D. Carroll, David J. Mathre, Edward G. Corley, Andrew S. Thompson
  • Inhibitors of farnesyl protein transferase
    Patent number: 5260465
    Abstract: This invention relates to pharmaceutical compounds of structural formula (I): ##STR1## and compositions and methods of treatment utilizing these compounds to inhibit farnesyl protein transferase and farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: December 16, 1991
    Date of Patent: November 9, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Sheo B. Singh, Deborah L. Zink
  • Inhibitors of farnesyl protein transferase
    Patent number: 5260479
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: December 16, 1991
    Date of Patent: November 9, 1993
    Assignee: Merck & Co., Inc.
    Inventor: Sheo B. Singh
  • Poly(orthocarbonate acetal) bioerodible polymers
    Patent number: 5254345
    Abstract: Polymers obtained by condensing polyols with divinyl orthocarbonates are useful for making bioerodible polymers for sustained release of beneficial agents.
    Type: Grant
    Filed: October 11, 1991
    Date of Patent: October 19, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Stefano A. Pogany, Gaylen M. Zentner
  • Cyclic renin inhibitors containing 3(S)-amino-4-cyclohexyl-2(R)-hydroxy-butanoic acid or 4-cyclo-hexyl-(2R, 3S)-dihydroxybutanoic acid or related analogs
    Patent number: 5254682
    Abstract: Compounds of the formula: ##STR1## are disclosed. These compounds inhibit the angiotensinogen-cleaving action of the natural proteolytic enzyme, renin, and are useful in treating, preventing or managing renin-associated hypertension, hyperaldosteronism, congestive heart failure, and glaucoma.
    Type: Grant
    Filed: June 11, 1991
    Date of Patent: October 19, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Daljit S. Dhanoa, Arthur A. Patchett, William J. Greenlee, William H. Parsons, Thomas A. Halgren, Ann E. Weber, Lihu Yang
  • Heteroarylnaphthalene hydroxy acids as inhibitors of leukotriene biosynthesis
    Patent number: 5252599
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: August 27, 1992
    Date of Patent: October 12, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Yves Girard, Rejean Fortin, Daniel Delorme, Daniel Dube, Pierre Hamel, Yves Ducharme, John W. Gillard
  • Fluorinated quinoline indoles as inhibitors of the biosynthesis of leukotrienes
    Patent number: 5252585
    Abstract: This invention relates to compounds having the formula I: ##STR1## wherein R.sup.1 is H, F or MeO, which are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: June 22, 1992
    Date of Patent: October 12, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Richard Frenette, John Hutchinson
  • Process for aromatic bromination
    Patent number: 5248817
    Abstract: A novel procedure for bromination of aromatic moieties utilizes N-bromosuccinimide or dibromodimethylhydantoin in an aqueous alkali medium. The bromination procedure is employed for the preparation of an intermediate used in the preparation of remoxipride, an antipsychotic compound.
    Type: Grant
    Filed: July 8, 1992
    Date of Patent: September 28, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Joseph Auerbach, Steven A. Weissman
  • Process for the preparation of bis(aryl)-phosphorohalidates
    Patent number: 5245069
    Abstract: This invention relates to a novel process for preparing bis(aryl)phosphorohalidates which are useful in the synthesis of various enol phosphates. The process of this invention provides a means of producing a high-yield, high-purity product without the need for costly crystallization or impractical, high temperature distillations.
    Type: Grant
    Filed: October 27, 1992
    Date of Patent: September 14, 1993
    Assignee: Merck & Co., Inc.
    Inventor: James W. McManus
  • Inhibitors of farnesyl protein transferase
    Patent number: 5245061
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and method for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: December 16, 1991
    Date of Patent: September 14, 1993
    Assignee: Merck & Co., Inc.
    Inventor: Sheo B. Singh
  • Thiol-reactive maleimido-based radiolabeling reagents
    Patent number: 5242680
    Abstract: Novel thiol-reactive maleimido-based radiolabeling reagents are disclosed which are useful for binding and receptor studies and assays. The reagents are also useful as diagnostic imaging agents, and as radiotherapeutic drugs.
    Type: Grant
    Filed: August 23, 1991
    Date of Patent: September 7, 1993
    Assignee: Merck & Co., Inc.
    Inventor: Michael Chorev
  • Antihypertensive compounds produced by fermentation
    Patent number: 5240910
    Abstract: Novel cyclic depsipeptides derived from a culture of Microbispora are antagonists of the receptor for endothelin, a potent vasoconstrictor, and are thus useful in treating cardiovascular disorders. Endothelin has other physiological effects, and the endothelin receptor antagonists of the present invention thus also have other therapeutic uses. The compounds are cyclical depsipeptides of N-(pyrrol-2-carboxy) - L-phe, D-allo-Thr, D-Phe, D-Ala, D- or L-dihydroxyphenyl-Gly, and D-dihydroxyphenyl-Gly.
    Type: Grant
    Filed: April 17, 1992
    Date of Patent: August 31, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Yiu-Kuen T. Lam, Deborah L. Zink, David L. Williams, Jr.
  • Process for converting the 13-.alpha.-hydroxy group of avermectin aglycones
    Patent number: 5241083
    Abstract: The natural stereochemistry at the 13-position of avermectin aglycones, normally .alpha.-oriented or below the plane of the molecule, is inverted or epimerized into the .beta.-position. The procedure starts with the avermectin aglycone compounds where the 13.alpha.-hydroxy group is activated to a mesylate leaving group. The resultant 13-.alpha.-mesylate is then displaced with a cesium carboxylate and one equivalent of the respective carboxylic acid, ending with the ester group being converted to the 13-.beta.-hydroxy configuration by transesterification in high yield.
    Type: Grant
    Filed: July 1, 1992
    Date of Patent: August 31, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Timothy Bill, Chris H. Senanayake, Robert D. Larsen, Sheo B. Singh, Thomas R. Vernhoeven
  • Inhibitors of farnesyl protein transferase
    Patent number: 5238922
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: September 30, 1991
    Date of Patent: August 24, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Samuel L. Graham, S. Jane deSolms, Victor M. Garsky
  • Synthesis of 4-methyl thiazole
    Patent number: 5231187
    Abstract: Isopropylidene methylamine is reacted with SO.sub.2 to form 4-methyl thiazole in the presence of a modified zeolite catalyst that has been ion-exchanged with an ammonium salt and porefilled with an alkali metal salt.
    Type: Grant
    Filed: October 1, 1991
    Date of Patent: July 27, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Bahjat S. Beshty, Frank P. Gortsema, George T. Wildman, John J. Sharkey
  • Avermectin difluoro derivatives
    Patent number: 5229416
    Abstract: Avermectin derivatives are disclosed which incorporate two fluorine atoms at the 4' monosaccharide position, the 4" disaccharide position or the 23 position. Avermectin aglycone derivatives are also disclosed which incorporate two fluorine atoms at position 13 or 23. These difluoro avermectin analogs are derived from corresponding ketones and enones which in turn are prepared by chemical modification of naturally occurring avermectins. These compounds are used as antiparisitic, insecticidal and antihelmintic agents in humans and animals and compositions containing such compounds as the active ingredient thereof are also disclosed.
    Type: Grant
    Filed: April 29, 1992
    Date of Patent: July 20, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Peter T. Meinke, Helmut Mrozik, Michael H. Fisher
  • .beta.-carbolines as cholecystokinin and gastrin antagonists
    Patent number: 5223509
    Abstract: This invention relates to certain .beta.-carbolines, which are antagonists of the functions of cholecystokinin (CCK) and gastrin, to pharmaceutical compositions comprising these compounds, and to the use of these compounds in the prevention and treatment of disorders of the gastrointestinal, central nervous and appetite-regulatory systems of mammals, especially of humans.
    Type: Grant
    Filed: February 21, 1992
    Date of Patent: June 29, 1993
    Assignee: Merck & Co., Inc.
    Inventor: Ben E. Evans